[ORGANIZATION]
Multiple sclerosis
Featured in 4 tracked stories · first seen
Situations
Quantum BioPharma MS therapy development
5 clusters · 9 sources · last updated
Latest: Quantum BioPharma receives ‘Buy’ rating for Lucid-MS candidate
In July 2026, Quantum BioPharma announced that its proprietary multiple‑sclerosis candidate LUCID‑MS had completed Phase 1 studies in healthy volunteers with a favorable safety profile and had filed an IND with the U.S.
CAR T-cell therapy market and research developments
3 clusters · 4 sources · last updated
Latest: CARsgen Therapeutics announces 2026 interim results
The global CAR T-cell therapy market is projected to experience significant growth through the end of the decade. Early projections estimated the market would reach approximately $13.56 billion by 2031, driven by rising
Also covered in
-
Ana Beatriz Nogueira Undergoes Ovarian Artery Procedure, Recovering
[CULTURE] · 16 sources ·